Hereditary Angioedema Market Forecast 2025-2034: Comprehensive Analysis And Growth Opportunities

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Projected Growth of the Hereditary Angioedema Market?
In the past few years, the hereditary angioedema market size has exhibited substantial growth. It is projected to expand from $2.62 billion in 2024 to $2.84 billion in 2025, recording a compound annual growth rate (CAGR) of 8.7%. Factors orchestrated in the historical surge include the rising incidence of hereditary angioedema, increased funding in research and development initiatives, a growing tally of approved drugs, enhanced product approval rates, and an upward trend in disposable incomes.

The market for hereditary angioedema is predicted to experience significant expansion in the approaching years. It is forecasted to reach a valuation of $3.93 billion in 2029 with a CAGR of 8.4%. The projected growth during this period can be traced back to factors such as the escalating incidences of rare diseases, amplification in healTH*Care expenditures, growing support from non-profit entities, enhanced understanding of hereditary angioedema and heightened knowledge about early detection. Key trends that are expected to arise in this period include technological progression, the innovation of new treatments, the introduction of novel medicines, sophisticated diagnostic tools, and advancements in the field of genetic testing.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22002

What Are the Different Hereditary Angioedema Market Segments?
The hereditary angioedema market covered in this report is segmented -

1) By Type: Hereditary Angioedema Type I, Hereditary Angioedema Type II
2) By Treatment Type: Prophylaxis, On-demand
3) By Drug Class: C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors, Other Drug Classes
4) By Route Of Administration: Subcutaneous, Intravenous, Oral
5) By Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency, Low C1-Inhibitor Levels, Reduced C1-Inhibitor Function
2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels, Dysfunctional C1-Inhibitor, Genetic Mutations In SERPING1 Gene

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22002&type=smp

What Are the Primary Drivers Shaping the Hereditary Angioedema Market?
The hereditary angioedema market is predicted to expand significantly due to the increasingly prevalent rate of rare diseases. These diseases, also referred to as orphan diseases, impact a minor portion of the population. This heightened rate of rare diseases can be attributed to several factors, including advancements in medical research, shifts in population demographics, and changes in environmental conditions. Hereditary angioedema (HAE) is one such notable rare disease that underscores the urgency for specialized treatments and heightened awareness due to the potential for fatal swelling incidents. Due to its infrequency and genetic features, preemptive diagnosis and specifically designed therapies are crucial for its effective handling and enhanced patient prognosis. As of June 2022, Rare Disease Advisor, a US-based online resource for healTH*Care professionals, estimates that HAE affects roughly 1 out of 50,000 people, with estimations varying from 1 in 10,000 to 1 in 150,000. HAE events in the United States are accountable for about 15,000 to 30,000 ER visits annually. Consequently, the escalating prevalence of rare diseases is bolstering the growth of the hereditary angioedema market.

Which Companies Are Leading in the Hereditary Angioedema Market?
Major companies operating in the hereditary angioedema market are Intellia Therapeutics Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co. Ltd., CSL Limited, Cipla Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Spark Therapeutics Inc., Pharming Group N.V., Pharvaris N.V., Astria Therapeutics Inc., CENTOGENE N.V., KalVista Pharmaceuticals Inc., ADARx Pharmaceuticals Inc., Adverum Biotechnologies Inc., Attune Pharmaceuticals Inc., Lev Pharmaceuticals Inc.

What Are the Major Trends Shaping the Hereditary Angioedema Market?
Major firms in the hereditary angioedema industry are pioneering creative solutions like oral plasma kallikrein inhibitors, enhancing patient treatment options with greater convenience and effectiveness. These inhibitors work by hampering the function of plasma kallikrein, curbing the overproduction of bradykinin, and are primarily prescribed for hereditary angioedema. For instance, KalVista Pharmaceuticals, Inc., a US-based firm, revealed in September 2024 that the FDA has given its nod to their new drug application (NDA) for the drug sebetralstat. This prospective oral plasma kallikrein inhibitor is designed for on-the-spot treatment of hereditary angioedema (HAE) attacks in both adult and pediatric patients aged 12 or more. By targeting and impeding plasma kallikrein activity, sebetralstat offers a fresh approach to treatment. The FDA's acceptance of the NDA marks a significant step forward towards possible approval and market launch.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report

What Are the Top Revenue-Generating Geographies in the Hereditary Angioedema Market?
North America was the largest region in the hereditary angioedema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Hereditary Angioedema Market?
2. What is the CAGR expected in the Hereditary Angioedema Market?
3. What Are the Key Innovations Transforming the Hereditary Angioedema Industry?
4. Which Region Is Leading the Hereditary Angioedema Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.